

Index

- aerosol mass spectrometer 116, 121
aerosol particle mass analyzer 116, 120
aerosol particles 116–17, 131–32
aerosols 91, 102, 106, 117, 120, 127, 132–34, 191, 252–53
agglomeration 45, 70, 137–38, 150, 241
algae 136, 138–39, 143, 154
alveoli 159, 186–88, 211, 223, 227–28
analysis
morphological 126, 129
single-particle chemical 126, 129
applications, nano-enabled 274
aquatic environment 135–40, 142, 144, 146–48, 150, 152, 154, 156
aquatic organisms 136, 138–41, 143, 148, 155
autoimmune diseases 288–89

background aerosols 104, 126
background particles 104, 128
BBB *see* blood–brain barrier
binding affinities 163–65
biodegradability 263, 268, 288, 302–3
biodegradable polymers 302–3
biomolecules 136, 144–46, 161, 166
biopharmaceuticals 280, 282–83, 288
blood–brain barrier (BBB) 202, 287–88, 310–11

brain 142, 155, 189, 208, 211, 213, 231, 287–88, 310–11, 357
bulk materials 220–21, 223, 229, 241, 249, 252, 306

cancer 83, 176, 189, 227, 286–87, 289, 295–96, 299
carbon footprint 332, 336–37
carbon nano-objects 12–13
carbon nanotube (CNT) 13–14, 17–18, 20–21, 25, 43–45, 47, 51–52, 56–59, 66–67, 71–74, 79, 82, 86–87, 89–90, 213–14
carrier particles 283, 308
catalysts 40–41, 44, 69, 82, 84–85, 149
caveolae 155, 171–73, 205
cell membrane 143, 160, 167, 175–78, 199, 283
cell wall 143, 167, 305
cells
animal 143
keratin 196
mammalian 149, 209
non-phagocytic 143–44
stem 194, 206
cellular uptake mechanisms 112, 167, 169, 171, 173
certified references materials (CRMs) 3, 22–23
characterization standards 20, 22
chemical agents 244, 246, 255
chemical industry 39, 69, 81–83, 92–94, 256
chemical safety report (CSR) 238, 240–42

- chemical vapor deposition (CVD) 32–33, 43, 45, 76
 classification, labeling and packaging (CLP) 237–39, 241, 244
 clathrin 170–71, 180, 205
 clathrin-mediated endocytosis 170–71
 clathrin-mediated endocytosis pathways 174, 185
 clinical trials 293, 296–98, 314
 CLP *see* classification, labeling and packaging
 CLP regulation 80, 239–40
 CNT *see* carbon nanotube
 CO_2 41, 51, 332, 335
 coated vesicles 170–71
 coatings 43, 66, 74, 76–77, 82, 86, 94, 102, 105–6, 127, 137, 139, 145, 302–3, 331
 concentration measurement techniques 115, 117, 119, 121
 condensation particle counters (CPCs) 117–19, 132
 consumer goods 81, 83, 89, 93
 control banding 247–48, 256
 corona formation 163, 165–66
 CPCs *see* condensation particle counters
 CRMs *see* certified references materials
 CSR *see* chemical safety report
 CVD *see* chemical vapor deposition
 cytosol 160, 167, 170, 173, 180, 182, 185
 cytotoxicity 145, 155, 166, 173, 176, 179, 184, 191, 204, 210
Daphnia magna 141, 151–52, 154
 dendritic cells 188, 190, 194, 212, 215, 289, 297, 312
 DEPs *see* diesel exhaust particles
 derived no-effect level (DNEL) 240
 diesel exhaust particles (DEPs) 189
 diffusion battery 116, 120–22
 DNA 72, 146, 161, 291–92
 DNEL *see* derived no-effect level dose–effect relationships 100–1, 110, 112, 127
 dosimetry 267–68
 drugs, protein 284
 dusts 227–28, 230, 232, 252–53
 electrical mobility classifiers 119–20
 electron microscopy 20–21, 154, 178–79, 184, 208, 211
 electrostatic precipitators 117–18, 122, 132
 endocytosis 144, 167, 169–71, 177, 182, 186, 204–5
 endosomes 170, 176, 182–83
 engineered nanoparticles (ENPs) 100–4, 106–7, 109–12, 117–18, 124, 127, 129, 149, 154, 200
 ENPs *see* engineered nanoparticles
 environment–organism barrier 140, 142
 environmental technology 85, 99, 256
 enzymatic degradation 281, 284–85, 302
 epithelial cells 142, 183–84, 190–91, 205
 epithelium 188, 190, 211, 213, 215
 exocytosis 206, 291
 exposure assessment 19, 241, 250–51, 277
 exposure mitigation 9, 262, 271–73, 277

- exposure risks 101–2
 exposure scenarios 228, 238, 240–43
 exposure studies 101–2, 106
- FCS *see* fluorescence correlation spectroscopy
 fluorescence correlation spectroscopy (FCS) 164–65, 203
- fullerenes 5–6, 8, 13–14, 17–18, 47, 50, 58, 71–72, 82, 90, 137, 264, 347
- GBP bulk materials 228–29
 GBP micromaterials 228–29
 GBP nanomaterial agglomerates 228
- genotoxicity 150, 189–90, 214, 263, 266
- glass, coated 331, 333
- graphene 13–14, 35, 44, 47, 50, 55–56, 58, 64, 71–72, 77
- hair follicle infundibulum 194, 197–98
- hair follicles 192–98, 216–18
- hair growth 193, 197
- hazardous chemicals 244, 246–47
- hazardous substances 235, 238–39, 246, 248, 253–56, 333
- HeLa cells 173, 177–80, 184, 204, 207
- HSA *see* human serum albumin
- human serum albumin (HSA) 146, 163–65
- humic acids 137–38, 148
- inhalation 91, 100, 107, 110–11, 128–29, 220, 223, 226, 228, 246, 249, 252
- intracellular distribution 175, 177, 179
- Langerhans cells 198–99
- laser scanning microscopy (LSM) 184, 191
- LCA *see* life-cycle assessment
- life-cycle assessment (LCA) 323–25
- liposomes 71, 83, 287, 290, 292–93, 296, 298, 304, 310
- liver 142, 181, 189, 209, 223, 231
- LSM *see* laser scanning microscopy
- lung 107, 109–12, 114, 118, 129–30, 159–60, 181, 186–89, 191–92, 203, 208, 211–13, 223, 228–30
- lung-associated lymph nodes 223
- lung cells 185, 189, 191, 208, 216
- lung epithelium 111, 114, 188, 231
- lung injury 207, 231
- macrophages 172, 188, 190, 212, 214–15, 224, 228, 289
- macropinocytosis 172–73, 175
- MDDC *see* monocyte-derived dendritic cells
- MDM *see* monocyte-derived macrophages
- mesothelioma 227, 230, 232, 254
- metal ions 142–43, 148, 290
- model ecosystems 136, 139, 148
- monocyte-derived dendritic cells (MDDC) 184, 191
- monocyte-derived macrophages (MDM) 184, 191
- motor proteins 176–77
- nanocoatings 74, 76, 84, 88, 96
- nanocomposites 14–15, 55, 58–59, 74–75, 94, 233
- nanodispersions 14–15
- nanoecotoxicology 135–36
- nanofibres 12–13, 71, 75, 130
- nanolayered silicates 73–75

- nanomaterial-based biomedical applications 181
- nanomaterial exposure 124–25
- nanomaterial products 23, 124
- nanomaterial release 125, 222
- nanomaterial risk assessment 222
- nanomaterial standardisation 10–11, 13, 15, 17, 19, 21, 23
- nanomaterial toxicology 221
- nanomaterials
- airborne 125, 134
 - applications of 30, 65, 81, 89–91, 295
 - carbon 44, 77, 90
 - cathode 22
 - classical 34, 47
 - commercial relevant 79, 92
 - economic relevance of 80, 92
 - engineered 11, 19, 22, 24, 54, 124, 134, 226, 229, 255
 - fibrous 226–27, 247
 - GBP 228–29
 - handling of 77, 93, 237
 - high production volume 219, 227
 - incidental 11
 - industrial use of 63, 80, 91–92
 - inorganic 333
 - manufactured 8, 11, 24, 59, 70, 72, 96–97, 151, 256–57, 259, 261–67, 269, 271–78
 - manufacturers of 78
 - modification of 92
 - safe handling of 235, 237, 239, 241, 243, 245, 247
- nanoparticle corona 162
- nanoparticle surface area monitor (NSAM) 118, 123, 128, 131–32
- nanoparticle toxicity 114, 130
- nanoparticles
- aerosolized 112
 - engineered 100
 - albumin 293
 - biodegradable polymeric 302
 - biologically induced transformation of 145
 - CALAA-01 295
 - cationic 299
 - ceramic 82
 - CeO₂ 155
 - co-polymeric 304
 - FePt 164, 203
 - bare 165
 - polymer-coated 165
 - fluorescence-labeled 179
 - fluorescent 204
 - gold 24, 72, 150, 152, 156, 166, 172–73, 179, 184–85, 200–1, 204, 207, 209, 210, 215, 222
 - high purity 40
 - industrial 308
 - inorganic 66, 287
 - intracellular trafficking of 179
 - iron 82, 85, 263
 - iron oxide 60, 68
 - lipidic 287
 - metal 24, 31, 36, 41
 - metal oxide 137–38
 - monodisperse 37, 52, 301
 - noble metal 88
 - PEG-coated 180
 - polymer 71
 - pullulan-based hydrogel 297
 - silica 131, 180, 206
 - amorphous 162
 - silver 68, 72, 137–38, 141–43, 145–46, 152–56, 210, 223, 232
 - SiO₂ 180
 - solid lipid 286

- subcellular distribution of 179
- super paramagnetic 25
- synthetic 341
- thioketal 286
- TiO₂ 65, 131, 152, 156
- nanopharmaceutical products 301–2, 306
- nanopharmaceuticals 280–81, 283, 285, 287, 289, 293, 295, 297, 299–302, 304–7, 313, 315
- nanoplates 12–13, 102, 130
- nano powders 14, 47, 51, 75, 256
- nanotechnological approaches 89
- nanotechnological development 82–83, 327
- nanotechnological products 319, 322
- nanotechnology, regulation of 351, 359
- nanotubes 13, 44, 49, 52, 66, 71, 74, 94
- nanowires 13, 69, 71
- NSAM *see* nanoparticle surface area monitor
- nucleic acids 64, 285–87, 299
- occupational exposure limit 228, 247–48
- occupational safety 219, 235, 237, 241, 243–46, 248, 254, 256, 328
- oxidative stress 146, 150, 152, 155–56, 189, 207, 210, 214, 231
- paclitaxel 293, 297–98, 312–13
- PEG *see* polyethylenglycol
- peptides 146, 173, 210, 283–84, 287, 291
- personal protective equipment 243, 253
- pharmaceuticals 84, 237, 283–84, 294, 296, 303, 308
- plasma membrane 160, 167, 170, 172–73, 176–78, 182, 284
- polyethylenglycol (PEG) 174, 179, 185, 286, 292, 294–95
- poorly soluble particles 189, 214, 227
- product carbon footprint 327, 330–31
- Product Sustainability Assessment (PROSA) 322–25, 339
- PROSA *see* Product Sustainability Assessment
- protein corona 145, 152, 154, 161–66, 201, 203, 316
- public attitude 300, 370–72
- QDs *see* quantum dots
- quantum dots (QDs) 13, 21, 47, 71–72, 75, 82, 86, 95, 137–40, 147, 150, 156, 186, 210–11
- reactive oxygen species (ROS) 146, 189
- respiratory tract 158, 186, 188, 208, 211–12, 215
- risk assessment 9, 54, 91, 110, 112, 148, 236–37, 241–42, 245–46, 250, 252, 272–75, 277–78, 347–48, 352–53
- risk communication 239, 341–44, 346, 348, 350, 352–56, 358, 360–66, 368–70, 372–75
 - participatory 364
- risk management 237, 273, 275, 348–49, 354, 361
- risk perception 327, 330–35, 342–45, 347, 353–54, 361, 372–73, 375
- risks, environmental 351

- ROS *see* reactive oxygen species
- severe plastic deformation (SPD) 32, 35, 60, 96
- silica 34, 47, 50, 70, 87, 91
- single-wall carbon nanotubes 13–14, 20–21, 25
- skin barrier 193, 198–99
- small-molecule drugs 281–82, 284
- SPD *see* severe plastic deformation
- stratum corneum* 160, 193–94
- sustainable development 319, 321, 323, 327, 336
- SWOT analysis 329–31, 333–34, 339
- toxicity, chemical 225–26
- tumors 286
- universal nanoparticle analyzer 119
- vaccination 286, 289–90
- zebrafish 142, 149, 151, 156
- zeolites 31, 40–41, 70